Cancer Immunotherapy for Hepatocellular Carcinoma: Current Drug Strategies, Resistance, Biomarkers, and Future Directions

医学 无容量 免疫疗法 肝细胞癌 贝伐单抗 阿替唑单抗 肿瘤科 彭布罗利珠单抗 易普利姆玛 索拉非尼 内科学 临床试验 佐剂 背景(考古学) 生物标志物 癌症 疾病 个性化医疗 重症监护医学 围手术期 免疫学 免疫检查点 临床终点 癌症免疫疗法 催眠药 肝癌 封锁 药品 CTLA-4号机组 卡铂 生物信息学 肝硬化
作者
Si-Si Zhong,Yang Yu,Xiao-Hui Zhong,Jun Xie,Maosheng Liu
出处
期刊:Drug Design Development and Therapy [Dove Medical Press]
卷期号:Volume 20: 1-32
标识
DOI:10.2147/dddt.s653279
摘要

Abstract: Hepatocellular carcinoma (HCC) usually develops in a chronically inflamed, fibrotic, and immunologically tolerogenic liver. This context shapes antitumor immunity, competing liver-related mortality, and access to subsequent therapy. As hepatic reserve, disease etiology, and regional treatment patterns differ substantially across patients and healthcare settings, immunotherapy outcomes are correspondingly heterogeneous. Immune-checkpoint inhibitors have transformed systemic treatment through combinations that target complementary immune, vascular, or signaling barriers. Atezolizumab plus bevacizumab established combined PD-L1 and VEGF inhibition, whereas STRIDE and nivolumab plus ipilimumab validated dual-checkpoint blockade with distinct CTLA-4 exposure. Camrelizumab plus rivoceranib confirmed the activity of PD-1 and VEGFR2 inhibition. Negative or mixed Phase III trials nevertheless show that biological rationale and higher response rates do not ensure a survival benefit. Immunotherapy is moving into intermediate-stage and perioperative disease, but the updated IMbrave050 findings illustrate the difficulty of achieving durable adjuvant benefit. No validated predictive biomarker currently guides selection among approved regimens. Furthermore, since most HCCs arise in a chronically diseased liver, hepatic reserve and liver-related competing mortality are central determinants of treatment eligibility, tolerance, and survival. This narrative review (literature search through May 31, 2026) is distinguished by its focus on hepatic reserve as a determinant of treatment selection and outcome, and by framing treatment failure as a composite of tumor-driven resistance and liver-related competing mortality. We synthesize evidence on clinical development, resistance, biomarkers, emerging therapies, underrepresented populations, hepatic reserve, and rational subsequent therapy. Further progress will depend on matching defined failure mechanisms to appropriate interventions while preserving hepatic reserve. Plain Language Summary: Hepatocellular carcinoma (HCC) is a common liver cancer that often develops in a liver already damaged by chronic inflammation, fibrosis, or cirrhosis. This damaged liver makes treatment more complex because doctors must control the cancer while preserving liver function. Immune checkpoint inhibitors, a type of immunotherapy, have changed treatment for advanced HCC, especially when combined with other drugs that target blood vessel growth or different immune checkpoints. However, not all combinations work equally well, and they are not interchangeable. Some patients benefit greatly, but many eventually experience cancer progression or suffer from worsening liver function. This review summarizes the current evidence on immunotherapy for HCC, focusing on why treatment failure should be seen as both cancer resistance and liver-related complications. We discuss how the liver’s immune environment, tumor blood vessels, and different checkpoint pathways influence treatment response. We also review biomarkers that may help select treatments, though none are yet validated for choosing among approved regimens. We highlight the importance of liver reserve—the liver’s remaining functional capacity—as a key factor in treatment decisions. Finally, we outline future research priorities: testing biomarkers in randomized trials, comparing treatment sequences, developing new therapies based on specific resistance mechanisms, and preserving liver function throughout treatment. This review is intended for clinicians and researchers who want a balanced, evidence-based overview of immunotherapy in HCC, with a particular emphasis on the liver as a critical organ that shapes both treatment outcomes and patient survival. Keywords: hepatocellular carcinoma, immunotherapy, immune-checkpoint inhibitor, combination therapy, biomarkers, resistance, hepatic reserve, precision oncology
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
lzz发布了新的文献求助10
1秒前
美好乐儿完成签到,获得积分10
1秒前
Nan完成签到,获得积分10
1秒前
1秒前
漫不经心完成签到,获得积分10
1秒前
朴素小馒头完成签到,获得积分10
1秒前
凉花落酒完成签到,获得积分10
2秒前
存存完成签到 ,获得积分10
2秒前
田様的应助被段晓倩采纳,获得10
2秒前
Martin的应助被木谦采纳,获得20
2秒前
李健的应助被纯真从寒采纳,获得10
2秒前
懒人完成签到,获得积分10
3秒前
3秒前
枫华西数发布了新的文献求助10
3秒前
MINGMING完成签到,获得积分10
3秒前
焦糖咸鱼发布了新的文献求助10
4秒前
筑梦完成签到,获得积分10
4秒前
现代菠萝完成签到,获得积分10
4秒前
twosix完成签到,获得积分10
4秒前
sunny发布了新的文献求助10
4秒前
MoChin完成签到,获得积分10
4秒前
夏夏子发布了新的文献求助10
4秒前
郭娅楠发布了新的文献求助10
5秒前
我想静静完成签到,获得积分10
5秒前
阿欢完成签到,获得积分10
5秒前
Lee_d发布了新的文献求助10
5秒前
懒惰依秋发布了新的文献求助10
5秒前
慕青的应助被miss张采纳,获得10
5秒前
YC发布了新的文献求助20
5秒前
樊庭完成签到,获得积分10
6秒前
苹果南烟发布了新的文献求助10
7秒前
天行马完成签到,获得积分10
7秒前
7秒前
水波不兴完成签到 ,获得积分10
7秒前
vegdog完成签到,获得积分10
7秒前
陆焉识完成签到 ,获得积分10
8秒前
123高人发布了新的文献求助10
8秒前
动如脱兔完成签到,获得积分10
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8152442
求助须知:如何正确求助?哪些是违规求助? 9549069
关于积分的说明 21690841
捐赠科研通 7740658
什么是DOI,文献DOI怎么找? 3425157
关于科研通互助平台的介绍 2550382
邀请新用户注册赠送积分活动 2468710